Developer docs
API playgroundTry for free, no card

Search company profiles

Bionest Partners

Full company profile

uuid0028m9l

Namestring
Bionest Partners
Websiteurl
bionest.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Bionest Partners is a Paris-headquartered strategic consulting firm founded in 2003 that provides advisory and management services to biotechnology and pharmaceutical companies operating in advanced therapeutics. Following its acquisition by Accenture, the firm operates as a specialized practice within Accenture's Life Sciences industry group, with stated global reach for client delivery. The company employs between 11 and 50 staff, organized as a boutique senior-strategist model with deep scientific credentials (multiple PhD-level leaders).

Bionest's service catalog is organized around three offerings. Advanced Therapeutics addresses go-to-market strategy, policy and advocacy, and patient access for precision medicine and cell and gene therapy products. Rare Disease provides strategic and scientifically informed support across pre-launch, launch, and post-launch phases for orphan indications. Ex-US Go-to-Market delivers cross-border commercialization planning — including revenue forecasting, go-direct G2M models, and financial/strategic/operational alignment — primarily for US biotechs expanding into the EU. Documented client engagements include a CAR-T-like Patient Support Program design, a two-year EU payer/political advocacy plan for a high-COGS gene therapy, a global CDx biomarker pre-launch framework, and a revenue forecast plus go-direct G2M recommendation for an orphan CNS EU launch.

Commercially, Bionest operates a professional services revenue model — project-based, quote-driven engagements with enterprise pharma and biotech clients. Pricing is not publicly disclosed. Distribution is direct through senior strategy executives, now augmented by Accenture's global life sciences sales force. The firm is privately held, wholly owned by Accenture (NYSE: ACN), with no independent funding, investor, or revenue disclosures available.

Short descriptiontext

Bionest Partners, founded in 2003 in Paris and now part of Accenture, provides strategic consulting to pharmaceutical and biotechnology companies, specializing in cell and gene therapy, rare disease, precision medicine, and ex-US market entry services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
life sciences consulting, biotech strategy advisory, cell and gene therapy consulting, rare disease strategy, pharma market access
Industry2 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Management Consulting Services54161
  • Other Scientific and Technical Consulting Services54169
SIC code1 code
  • Services-Management Consulting Services8742
Product category
Life Sciences Consulting
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Strategic Consulting Services
TypeProfessional Services
Description

Professional services revenue generated through strategic consulting engagements with life sciences companies in advanced therapeutics, rare diseases, and precision medicine. Services include go-to-market strategy, policy and advocacy, patient support programs, and market access planning.

accenture.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Bionest Partners provides specialized strategic consulting services to pharmaceutical and biotechnology companies developing advanced therapeutics, with deep focus on cell and gene therapies, rare diseases, and precision medicine. Engagements span go-to-market strategy, commercial, medical and access strategies, patient support program design, biomarker market access planning, EU payer and political landscape shaping, and ex-US go-to-market execution. The firm delivers these services as a specialized practice within Accenture's global Life Sciences group.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Developed impactful Patient Support Program (PSP) solutions tailored to market requirements for CGT with CAR-T-like patient journey
+3 more records
Product overview1 text field

Bionest is a specialized consulting practice within Accenture's Life Sciences industry group that provides strategic advisory services for advanced therapeutics, rare diseases, and international market expansion. The three core service offerings—Advanced Therapeutics (covering precision medicine, cell and gene therapies, and policy/advocacy), Rare Disease (spanning pre-launch to post-launch strategy), and Ex-US Go-to-Market (enabling international market entry and execution)—collectively help life sciences clients navigate the transformative landscape of cell and gene therapies, oncology, CNS disorders, and autoimmune conditions.

Product and service3 records
1Advanced Therapeutics Consulting
CategoryLife Sciences Strategy Consulting
Description

Strategic consulting service that helps pharmaceutical and biotechnology clients navigate precision medicine and cell and gene therapy commercialization, covering go-to-market strategy, policy and advocacy, and related commercial, medical, and access strategies for advanced therapeutics.

2Rare Disease Consulting
CategoryLife Sciences Strategy Consulting
Description

Consulting service delivering strategic and scientifically informed guidance to companies developing rare disease indications before, during, and after launch, supporting successful commercial, medical, and access strategies.

3Ex-US Go-to-Market Consulting
CategoryLife Sciences Strategy Consulting
Description

Consulting service that guides biotech and pharma clients in crafting objective ex-US go-to-market strategies, providing financial, strategic, and operational alignment for successful execution in international markets, with a particular emphasis on EU entry.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bionest was acquired by Accenture to expand the company's capabilities in life sciences consulting. The acquisition brings specialized expertise in rare diseases, gene therapy, and precision medicine to Accenture's global life sciences practice. Bionest operates as a specialized service offering within Accenture's Life Sciences division, providing strategic consulting services for advanced therapeutics and cell and gene therapies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Life sciences commercial strategy and insights firm offering consulting, analytics, and evidence services to biopharma across launch, brand strategy, and market access. Direct competitor for enterprise life sciences advisory engagements.

TypeDirect peer
Description

Life sciences-focused strategy consulting firm serving biotech, pharma, and medtech with commercial, medical, and corporate strategy. Overlaps directly with Bionest on rare disease and advanced therapy commercial advisory.

TypeBroad incumbent
Description

Global management consulting firm with a deep life sciences practice advising on commercial strategy, M&A, and market access. Overlaps with Bionest on biopharma commercial strategy engagements.

TypeDirect peer
Description

Boutique life sciences strategy consulting firm advising biopharma on commercial strategy, market access, and launch planning for specialty and rare disease products. Closely comparable to Bionest in service mix and client base.

TypeDirect peer
Description

Strategy consulting firm focused exclusively on life sciences, advising on commercial strategy, portfolio prioritization, and new product planning for pharma and biotech. Direct competitor for specialty and advanced therapeutics engagements.

TypeBroad incumbent
Description

Global life sciences services platform offering consulting, real-world evidence, and commercial strategy alongside its core data and CRO businesses. Represents the largest scaled competitor for biopharma strategy advisory.

TypeBroad incumbent
Description

Global professional services firm with a Life Sciences strategy practice advising on commercial transformation, market access, and operating model design. Comparable enterprise-scale advisory competitor.

8ZS Associates
TypeBroad incumbent
Description

Large global consulting firm with a substantial life sciences practice covering strategy, sales, and marketing. Competes for strategic commercial advisory work and offers broader scale than Bionest.

TypeBroad incumbent
Description

Global consulting firm with a Life Sciences practice providing commercial strategy, pricing, and market access advice to biopharma. Broad incumbent competing for similar advisory mandates.

TypeDirect peer
Description

Specialist biopharmaceutical strategy consultancy advising on product strategy, market access, and commercialization for innovative therapeutics. Comparable niche focus on specialty and rare disease assets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bionest Partners

Life Sciences Consultingbionest.com

Bionest Partners, founded in 2003 in Paris and now part of Accenture, provides strategic consulting to pharmaceutical and biotechnology companies, specializing in cell and gene therapy, rare disease, precision medicine, and ex-US market entry services.

What Bionest Partners does

Bionest Partners is a Paris-headquartered strategic consulting firm founded in 2003 that provides advisory and management services to biotechnology and pharmaceutical companies operating in advanced therapeutics. Following its acquisition by Accenture, the firm operates as a specialized practice within Accenture's Life Sciences industry group, with stated global reach for client delivery. The company employs between 11 and 50 staff, organized as a boutique senior-strategist model with deep scientific credentials (multiple PhD-level leaders).

Bionest's service catalog is organized around three offerings. Advanced Therapeutics addresses go-to-market strategy, policy and advocacy, and patient access for precision medicine and cell and gene therapy products. Rare Disease provides strategic and scientifically informed support across pre-launch, launch, and post-launch phases for orphan indications. Ex-US Go-to-Market delivers cross-border commercialization planning — including revenue forecasting, go-direct G2M models, and financial/strategic/operational alignment — primarily for US biotechs expanding into the EU. Documented client engagements include a CAR-T-like Patient Support Program design, a two-year EU payer/political advocacy plan for a high-COGS gene therapy, a global CDx biomarker pre-launch framework, and a revenue forecast plus go-direct G2M recommendation for an orphan CNS EU launch.

Commercially, Bionest operates a professional services revenue model — project-based, quote-driven engagements with enterprise pharma and biotech clients. Pricing is not publicly disclosed. Distribution is direct through senior strategy executives, now augmented by Accenture's global life sciences sales force. The firm is privately held, wholly owned by Accenture (NYSE: ACN), with no independent funding, investor, or revenue disclosures available.

Bionest Partners firmographics

Firmographics
Name
Bionest Partners
Website
https://bionest.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
Bionest Partners, founded in 2003 in Paris and now part of Accenture, provides strategic consulting to pharmaceutical and biotechnology companies, specializing in cell and gene therapy, rare disease, precision medicine, and ex-US market entry services.
Ownership category
akta.pro rank

Bionest Partners industry classification

Industry
Product category
Life Sciences Consulting
NAICS
Management Consulting Services (54161), Other Scientific and Technical Consulting Services (54169)
SIC
Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Life sciences consulting
  • Biotech strategy advisory
  • Cell and gene therapy consulting
  • Rare disease strategy
  • Pharma market access

Where Bionest Partners is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Markets served

Bionest Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Strategic Consulting Services: Professional services revenue generated through strategic consulting engagements with life sciences companies in advanced therapeutics, rare diseases, and precision medicine. Services include go-to-market strategy, policy and advocacy, patient support programs, and market access planning.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Bionest Partners product offering

Product offering

Core offering

Bionest Partners provides specialized strategic consulting services to pharmaceutical and biotechnology companies developing advanced therapeutics, with deep focus on cell and gene therapies, rare diseases, and precision medicine. Engagements span go-to-market strategy, commercial, medical and access strategies, patient support program design, biomarker market access planning, EU payer and political landscape shaping, and ex-US go-to-market execution. The firm delivers these services as a specialized practice within Accenture's global Life Sciences group.

Product overview

Bionest is a specialized consulting practice within Accenture's Life Sciences industry group that provides strategic advisory services for advanced therapeutics, rare diseases, and international market expansion. The three core service offerings—Advanced Therapeutics (covering precision medicine, cell and gene therapies, and policy/advocacy), Rare Disease (spanning pre-launch to post-launch strategy), and Ex-US Go-to-Market (enabling international market entry and execution)—collectively help life sciences clients navigate the transformative landscape of cell and gene therapies, oncology, CNS disorders, and autoimmune conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Advanced Therapeutics Consulting Strategic consulting service that helps pharmaceutical and biotechnology clients navigate precision medicine and cell and gene therapy commercialization, covering go-to-market strategy, policy and advocacy, and related commercial, medical, and access strategies for advanced therapeutics.
  • Rare Disease Consulting Consulting service delivering strategic and scientifically informed guidance to companies developing rare disease indications before, during, and after launch, supporting successful commercial, medical, and access strategies.
  • Ex-US Go-to-Market Consulting Consulting service that guides biotech and pharma clients in crafting objective ex-US go-to-market strategies, providing financial, strategic, and operational alignment for successful execution in international markets, with a particular emphasis on EU entry.

Quantifiable outcome

  • Developed impactful Patient Support Program (PSP) solutions tailored to market requirements for CGT with CAR-T-like patient journey
  • +3 more outcomes

Companies that use Bionest Partners

Customer profile

Segments3 records

Ideal customer profiles1 record

Bionest Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Bionest Partners partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • AccenturecoreStrategic or Co-development PartnerBionest was acquired by Accenture to expand the company's capabilities in life sciences consulting. The acquisition brings specialized expertise in rare diseases, gene therapy, and precision medicine to Accenture's global life sciences practice. Bionest operates as a specialized service offering within Accenture's Life Sciences division, providing strategic consulting services for advanced therapeutics and cell and gene therapies.

Scale indicators1 record

Recent moves7 records

Expansion highlights5 records

Bionest Partners competitors and assessment

Company assessment

Direct peers

  • Trinity Life Sciences: Life sciences commercial strategy and insights firm offering consulting, analytics, and evidence services to biopharma across launch, brand strategy, and market access. Direct competitor for enterprise life sciences advisory engagements.
  • ClearView Healthcare Partners: Life sciences-focused strategy consulting firm serving biotech, pharma, and medtech with commercial, medical, and corporate strategy. Overlaps directly with Bionest on rare disease and advanced therapy commercial advisory.
  • Putnam Associates: Boutique life sciences strategy consulting firm advising biopharma on commercial strategy, market access, and launch planning for specialty and rare disease products. Closely comparable to Bionest in service mix and client base.
  • Health Advances: Strategy consulting firm focused exclusively on life sciences, advising on commercial strategy, portfolio prioritization, and new product planning for pharma and biotech. Direct competitor for specialty and advanced therapeutics engagements.
  • Defined Health (Cello Health): Specialist biopharmaceutical strategy consultancy advising on product strategy, market access, and commercialization for innovative therapeutics. Comparable niche focus on specialty and rare disease assets.

Broad incumbents

  • L.E.K. Consulting: Global management consulting firm with a deep life sciences practice advising on commercial strategy, M&A, and market access. Overlaps with Bionest on biopharma commercial strategy engagements.
  • IQVIA: Global life sciences services platform offering consulting, real-world evidence, and commercial strategy alongside its core data and CRO businesses. Represents the largest scaled competitor for biopharma strategy advisory.
  • Huron Consulting Group: Global professional services firm with a Life Sciences strategy practice advising on commercial transformation, market access, and operating model design. Comparable enterprise-scale advisory competitor.
  • ZS Associates: Large global consulting firm with a substantial life sciences practice covering strategy, sales, and marketing. Competes for strategic commercial advisory work and offers broader scale than Bionest.
  • Charles River Associates: Global consulting firm with a Life Sciences practice providing commercial strategy, pricing, and market access advice to biopharma. Broad incumbent competing for similar advisory mandates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Bionest Partners social profiles

Digital presence

Bionest Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bionest Partners leadership team

Management profile

Number of profiles

Profiles6 records

Bionest Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bionest Partners M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bionest Partners

What does Bionest Partners do?

Bionest Partners provides specialized strategic consulting services to pharmaceutical and biotechnology companies developing advanced therapeutics, with deep focus on cell and gene therapies, rare diseases, and precision medicine. Engagements span go-to-market strategy, commercial, medical and access strategies, patient support program design, biomarker market access planning, EU payer and political landscape shaping, and ex-US go-to-market execution. The firm delivers these services as a specialized practice within Accenture's global Life Sciences group.

Is Bionest Partners a public or private company?

Bionest Partners is a private company. It is classified as corporate owned and is currently operating.

When was Bionest Partners founded?

Bionest Partners was founded in 2003. It employs 11 to 50 people.

Where is Bionest Partners based?

Bionest Partners is headquartered in Paris, France, in the Europe region.

How does Bionest Partners make money?

One revenue line is on record: strategic Consulting Services.

Who are Bionest Partners's main competitors?

Direct peers on record are Trinity Life Sciences, ClearView Healthcare Partners, Putnam Associates, Health Advances and Defined Health (Cello Health). Broad incumbents are L.E.K. Consulting, IQVIA, Huron Consulting Group, ZS Associates and Charles River Associates.

Does Bionest Partners have an API?

No public API is recorded for Bionest Partners.

What industry is Bionest Partners in?

Bionest Partners's product category is Life Sciences Consulting. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 54161 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsAccenture Acquires BionestAccenture has acquired Bionest, a New York-based consulting firm specializing in the life sciences sector. The acquisition adds 46 consultants to Accenture Strategy's Life Sciences practice to enhance its capabilities in go-to-market strategy and operational execution. The financial terms of the deal were not disclosed.PharmiWeb.comAccenture Expands Strategy Capabilities in Life Sciences with the Acquisition of BionestAccenture acquired Bionest, a strategy and consulting firm for biopharma organizations, adding its 46-person team to Accenture Strategy in Life Sciences. Bionest focuses on go-to-market strategy in areas like oncology, precision medicine, and cell and gene therapy. Terms of the transaction were not disclosed.AccentureAccenture Expands Strategy Capabilities in Life Sciences with the Acquisition of BionestAccenture has acquired Bionest, a specialized consulting firm with 46 experts in life sciences strategy, to expand its capabilities within the Accenture Strategy Life Sciences practice. This acquisition aims to help biopharma companies navigate complex commercialization challenges and leverage new scientific advancements for patient health. Terms of the transaction were not disclosed.PR NewswireBOSTON-PARIS Biotechnology Summit®: Bringing Together Leaders to Bridge Business PartnershipsThe second annual BOSTON-PARIS Biotechnology Summit® will be held on June 3, 2018, at the Boston Exchange Center, aiming to foster innovation and partnerships between trans-Atlantic biotechnology and pharmaceutical stakeholders. The conference will feature executives from Ipsen, Johnson & Johnson, Relay Therapeutics, and Nightstar Therapeutics as speakers, alongside major sponsors including McDermott Will & Emery, BIONEST Partners, Nanobiotix, and 4Clinics. Topics will cover entering and penetrating US and French financial, regulatory, and customer markets, with discussions on talent, science, and business strategies for biotechnology companies ranging from startups to mature firms.